Johnson & Johnson (NYSE:JNJ) Receives $253.04 Consensus Target Price from Analysts

Shares of Johnson & Johnson (NYSE:JNJ) have been assigned an average recommendation of “Moderate Buy” from the twenty-seven brokerages that are covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold rating and twenty have issued a buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $253.0435.

Several equities research analysts have commented on JNJ shares. Sanford C. Bernstein upped their target price on shares of Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a research note on Wednesday, April 15th. Rothschild & Co Redburn upped their target price on shares of Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a research note on Thursday, February 19th. Weiss Ratings downgraded shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b)” rating in a research note on Friday, April 24th. HSBC upped their target price on shares of Johnson & Johnson from $265.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Finally, Wells Fargo & Company raised their price objective on shares of Johnson & Johnson from $240.00 to $263.00 and gave the stock an “overweight” rating in a report on Wednesday, April 15th.

Institutional Investors Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently made changes to their positions in JNJ. AustralianSuper Pty Ltd grew its position in shares of Johnson & Johnson by 632.0% in the 3rd quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company’s stock valued at $16,536,000 after acquiring an additional 77,000 shares during the period. J.W. Cole Advisors Inc. grew its position in shares of Johnson & Johnson by 2.2% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company’s stock valued at $24,278,000 after acquiring an additional 2,769 shares during the period. Guinness Asset Management LTD grew its position in shares of Johnson & Johnson by 0.4% in the 3rd quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company’s stock valued at $251,216,000 after acquiring an additional 5,994 shares during the period. Greenberg Financial Group bought a new position in shares of Johnson & Johnson in the 4th quarter valued at about $954,000. Finally, National Pension Service grew its position in shares of Johnson & Johnson by 3.2% in the 3rd quarter. National Pension Service now owns 4,926,569 shares of the company’s stock valued at $913,484,000 after acquiring an additional 151,707 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Down 0.2%

Shares of NYSE:JNJ opened at $223.00 on Wednesday. Johnson & Johnson has a 52 week low of $149.04 and a 52 week high of $251.71. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The company has a market capitalization of $536.81 billion, a PE ratio of 25.78, a PEG ratio of 2.19 and a beta of 0.26. The company has a 50 day moving average price of $232.75 and a two-hundred day moving average price of $225.29.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. During the same quarter in the prior year, the firm earned $2.77 earnings per share. The business’s quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Analysts forecast that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be issued a dividend of $1.34 per share. The ex-dividend date is Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.4%. Johnson & Johnson’s dividend payout ratio (DPR) is 61.97%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported that nipocalimab met the primary endpoint in the Phase 2 JASMINE study for lupus, with disease control sustained through 52 weeks and better results in autoantibody-positive patients, reinforcing the drug’s commercial potential. Article Title
• Positive Sentiment: New Phase 2 DAHLIAS biomarker analyses in Sjögren’s disease showed stronger clinical responses among patients with higher autoantibody and IgG levels, supporting nipocalimab’s potential in another autoimmune indication. Article Title
• Neutral Sentiment: Scotiabank reiterated a Buy rating on Johnson & Johnson, which may have helped support investor confidence but does not materially change the company’s fundamentals. Article Title
• Neutral Sentiment: Jim Cramer highlighted J&J as a defensive stock to own outside the AI trade, reinforcing the name’s appeal as a diversification play rather than signaling a new company-specific catalyst. Article Title

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.